Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3171/foc.2003.14.3.11 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 (PIMS-TS), also known as multisystem inflammatory syndrome in children (MIS-C) emerged in April, 2020. The paediatric comparisons within the RECOVERY trial aimed to assess the effect of intravenous immunoglobulin or corticosteroids compared with usual care on duration of hospital stay for children with PIMS-TS and to compare tocilizumab (anti-IL-6 receptor monoclonal antibody) or anakinra (anti-IL-1 receptor antagonist) with usual care for those with inflammation refractory to initial treatment.
Methods: We did this randomised, controlled, open-label, platform trial in 51 hospitals in the UK.
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Lancet Diabetes Endocrinol
December 2023
Background: Empagliflozin has been proposed as a treatment for COVID-19 on the basis of its anti-inflammatory, metabolic, and haemodynamic effects. The RECOVERY trial aimed to assess its safety and efficacy in patients admitted to hospital with COVID-19.
Methods: In the randomised, controlled, open-label RECOVERY trial, several possible treatments are compared with usual care in patients hospitalised with COVID-19.
Article Synopsis
- A study evaluated the effects of a higher dose of corticosteroids on COVID-19 patients who needed oxygen or ventilatory support, building on previous findings that low-dose corticosteroids reduced mortality in similar patients.
- The research was part of the RECOVERY trial, which randomly assigned patients to receive either higher dose corticosteroids or usual care with a lower dose, measuring 28-day mortality rates as the primary outcome.
- From May 2021 to May 2022, 1,272 patients were included, with notable participation from Asia and the UK; results showed that nearly all of the patients who received usual care also received some form of low-dose corticosteroids.
A process evaluation of Promotional Guides used by health visitors to support men's transition to fatherhood: a qualitative study.
Perspect Public Health
March 2024
The University of Warwick, Coventry, UK.
Background: Health visitors play an important role in supporting new parents in their transition to parenthood. A programme known as the Promotional Guide system is used by many health visitors in England with mothers and fathers to support this transition, but there is little known about health visitors' views of the Promotional Guides, how they are used in practice or barriers to effective implementation with fathers.
Aims: The aim of this study was to explore the following: (1) health visitors' use of Promotional Guides with fathers, (2) health visitors' assessment of father's mental health and wellbeing and (3) facilitators and barriers to using Promotional Guides in practice.
Background: We aimed to evaluate the use of baricitinib, a Janus kinase (JAK) 1-2 inhibitor, for the treatment of patients admitted to hospital with COVID-19.
Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple possible treatments in patients hospitalised with COVID-19 in the UK. Eligible and consenting patients were randomly allocated (1:1) to either usual standard of care alone (usual care group) or usual care plus baricitinib 4 mg once daily by mouth for 10 days or until discharge if sooner (baricitinib group).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!